InspireMD (NSPR) to Release Quarterly Earnings on Tuesday

InspireMD (NYSE:NSPR - Get Free Report) is scheduled to announce its earnings results before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Investors that are interested in registering for the company's conference call can do so using this link.

InspireMD (NYSE:NSPR - Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.03). The firm had revenue of $1.74 million for the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative return on equity of 62.02% and a negative net margin of 388.67%. During the same quarter last year, the business posted ($0.24) EPS. On average, analysts expect InspireMD to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

InspireMD Stock Performance

Shares of NYSE NSPR traded down $0.07 during trading hours on Tuesday, reaching $2.40. 16,928 shares of the stock were exchanged, compared to its average volume of 23,950. The firm has a market capitalization of $59.83 million, a price-to-earnings ratio of -3.24 and a beta of 0.93. InspireMD has a 52 week low of $1.81 and a 52 week high of $3.48. The stock's fifty day simple moving average is $2.64 and its 200 day simple moving average is $2.57.

Wall Street Analyst Weigh In

NSPR has been the topic of a number of analyst reports. Piper Sandler reissued an "overweight" rating and set a $4.50 price target on shares of InspireMD in a research report on Tuesday, September 17th. StockNews.com initiated coverage on InspireMD in a research report on Saturday. They set a "sell" rating on the stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.